Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma
with Acquired High-level HER2 Amplification: A Case Report

Trastuzumab deruxtecan is a newly developed antibody-drug conjugate (ADC) designed to overcome human epidermal growth factor receptor 2 (HER2) aberrations. Studies have confirmed that Trastuzumab deruxtecan yields promising efficacy with a manageable safety profile in previously treated non-small ce...

Description complète

Détails bibliographiques

Auteurs principaux:	Xiaoxiao GE, Hefeng CHEN, Shaohua CUI
Format:	Artigo
Langue:	Chinês
Publié:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2026-03-01
Collection:	Chinese Journal of Lung Cancer
Sujets:	lung neoplasms trastuzumab deruxtecan her2 amplification acquired resistance case report
Accès en ligne:	http://dx.doi.org/10.3779/j.issn.1009-3419.2026.104.01
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!